u/Avish_Golakiya · 78d ago31 prior · 63% at 3mo
10 penny biotechs I'm watching for August 2026, and adding slowly
Zura Oncology's tibulizumab in hidradenitis has topline data expected this quarter. The stock shows 8-fund accumulation (72% last quarter), insider buying, and ~33 months of cash runway, creating a favorable setup for a volatile move on near-term clinical readout.
At post $5.64Now $4.13-26.8% since postedas of Oct 22, 9:00 AM ET
1d+1.2%
3d+5.8%
1w+2.5%
1m+10.5%
3m—
6m—
1y—